TriangleTalquetamab (NCT07093554)
Talquetamab trial for Relapsed/Refractory Multiple Myeloma (NCT07093554). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for multiple myeloma that has returned or not responded, in adults who have had at least one earlier line of therapy and are eligible for two approved treatments.
The idea: use the waiting time. After cells are collected, patients receive one cycle of talquetamab while their CAR T cells are manufactured. Then they receive lymphodepleting chemotherapy and the CAR T therapy cilta cel.
This phase 1b trial plans 31 patients and measures safety first. At the Medical College of Wisconsin in Milwaukee, Othman Akhtar leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.